Abstract
Antisense-mediated exon skipping is an attractive tool to study gene function as well as a promising therapeutic application for a number of diseases. In order for antisense oligonucleotides (AONs) to induce effective exon skipping during pre-mRNA splicing, they have to fulfill certain criteria. These include resistance against endo- and exonucleases and RNase H-induced cleavage and suitable thermodynamic properties. Furthermore, the AON-target sequence needs to be accessible and should contain sequence motives that are essential for proper inclusion of the exon into the mRNA. For most genes, only a few AONs have been designed, with the exception of the DMD gene, for which over 400 AONs targeting the majority of DMD exons have been reported. This allows retrospective analysis of effective and ineffective AONs to obtain guidelines to optimize future AON design.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aartsma-Rus A, van Ommen GJ (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13:1609–1624
Aartsma-Rus A (2010) Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biol 7:453–461
Aartsma-Rus A, Winter CL, Janson AAM et al (2005) Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15:284–297
Aartsma-Rus A, van Vliet L, Hirschi M et al (2009) Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17:548–553
Aartsma-Rus A, Houlleberghs H, van Deutekom JC et al (2010) Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing. Oligonucleotides 20:69–77
Popplewell LJ, Trollet C, Dickson G et al (2009) Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther 17:554–561
Wilton SD, Fall AM, Harding PL et al (2007) Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 15:1288–1296
Aartsma-Rus A, Singh KH, Fokkema IF et al (2010) Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet 18:889–894
Aartsma-Rus A, van der Maarel S (2010) Reply to Levy et al. Eur J Hum Genet 18:971
van Ommen GJ, van Deutekom J, Aartsma-Rus A (2008) The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 10:140–149
Aartsma-Rus A, Kaman WE, Bremmer-Bout M et al (2004) Comparative analysis of antisense oligonucleotide analogs for tageted DMD exon 46 skipping in muscle cells. Gene Ther 11:1391–1398
Alter J, Lou F, Rabinowitz A et al (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175–177
Heemskerk H, de Winter C, van Kuik P et al (2010) Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 18:1210–1217
Heemskerk HA, De Winter CL, de Kimpe SJ et al (2009) In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11:257–266
Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198–203
Malerba A, Thorogood FC, Dickson G et al (2009) Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 20:955–965
Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270:1628–1644
Sproat BS, Lamond AI, Beijer B et al (1989) Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res 17:3373–3386
De Clercq E, Eckstein F, Sternbach H et al (1969) Interferon induction by and ribonuclease sensitivity of thiophosphate-substituted polyribonucleotides. Antimicrob Agents Chemother 9:187–191
Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187–195
Heemskerk H, De Winter CL, van Ommen GJ et al (2009) Development of antisense-mediated exon skipping as a treatment for Duchenne muscular dystrophy. Ann N Y Acad Sci 1175:71–79
Harding PL, Fall AM, Honeyman K et al (2007) The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther 15:157–166
Wee KB, Pramono ZA, Wang JL et al (2008) Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides. PLoS One 3:e1844
Mathews DH, Sabina J, Zuker M et al (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 288:911–940
Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31:3406–3415
Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298
Desmet FO, Hamroun D, Lalande M et al (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67
Aartsma-Rus A, Kaman WE, Weij R et al (2006) Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 14:401–407
Adams AM, Harding PL, Iversen PL et al (2007) Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol 8:57
Aartsma-Rus A, van Ommen GJ, Kaplan JC (2010) Innovating therapies for muscle diseases. In: Dulac O, Lassonde M, Sarnat H (eds) Handbook of clinical neurology, 3rd series, 3rd edn. Elsevier, Chennai, India
Acknowledgments
Willeke van Roon and Mark Einderhand are acknowledged for proofreading the manuscript and helpful comments and suggestions. The author receives funding from ZonMw (the Netherlands), the Dutch Duchenne Parent Project (the Netherlands), Spieren voor spieren (Prinses Beatrix Foundation, the Netherlands), and the European Union (LUMC is partner in the TREAT-NMD network of excellence (LSHM-CT-2006-036825) and the BIO-NMD project (HEALTH-F2-2009-241665)). The LUMC participates in the Center for Biomedical Genetics (the Netherlands) and the Center for Medical Systems Biology (the Netherlands).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Aartsma-Rus, A. (2012). Overview on AON Design. In: Aartsma-Rus, A. (eds) Exon Skipping. Methods in Molecular Biology, vol 867. Humana Press. https://doi.org/10.1007/978-1-61779-767-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-61779-767-5_8
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-766-8
Online ISBN: 978-1-61779-767-5
eBook Packages: Springer Protocols